Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 18.12M P/E - EPS this Y 22.20% Ern Qtrly Grth -
Income -24.54M Forward P/E -0.31 EPS next Y - 50D Avg Chg -53.00%
Sales 42.81M PEG - EPS past 5Y - 200D Avg Chg -77.00%
Dividend N/A Price/Book 1.07 EPS next 5Y - 52W High Chg -89.00%
Recommedations 3.00 Quick Ratio 2.72 Shares Outstanding 98.94M 52W Low Chg 36.00%
Insider Own 7.44% ROA -14.76% Shares Float 61.19M Beta 0.50
Inst Own 39.36% ROE -89.76% Shares Shorted/Prior 134.13K/70.73K Price 0.22
Gross Margin 2.36% Profit Margin -57.33% Avg. Volume 2,754,229 Target Price -
Oper. Margin -422.02% Earnings Date May 8 Volume 1,048,157 Change 0.45%
About Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals, Inc. News
11:10 AM Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
03/27/24 Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
12/18/23 Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%
08:10 AM Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
09/25/23 Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
08/24/23 Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis
08/23/23 Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
08/17/23 Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
07:40 AM Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
07/18/23 Why Pieris Pharmaceuticals Shares Shooting Higher Today?
07/18/23 Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
07/17/23 3 Doomed Biotech Stocks Destined for Disaster
06/23/23 Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
06/21/23 Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
06/11/23 We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
06/02/23 Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
05/22/23 Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
05/21/23 Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
05/15/23 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially
05/11/23 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
PIRS Chatroom

User Image Unknmarket Posted - 2 hours ago

🫣

User Image vue556 Posted - 2 hours ago

User Image moliva Posted - 3 hours ago

User Image Rabinovich Posted - 4 hours ago

$PIRS Are you guys gonna hold through RS? I can't say what will happen with the SP in this case but normally, as most of you know, it ain't pretty.

User Image Stock_Titan Posted - 5 hours ago

$PIRS Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split https://www.stocktitan.net/news/PIRS/pieris-pharmaceuticals-announces-1-for-80-reverse-stock-2u8h3z8gwonw.html

User Image wahoowa96 Posted - 5 hours ago

$PIRS I rounded up to 4K…for 1:80 rs on 4/22. Cash flow good by 2027.

User Image DRPUMP Posted - 7 hours ago

User Image dhovekamp42 Posted - 15 hours ago

There is nothing misleading in the press release and associated $PIRS filing - for issues you try to explain read the explanations of risks especially "baby shelf" and "split" in https://stocktwits.com/dhovekamp42/message/568530208

User Image Rabinovich Posted - 23 hours ago

$PIRS Giuseppe, did you manage to sell the furniture?

User Image NeilG Posted - 1 day ago

$PIRS Question: why isn’t anyone discussing the reverse split that’s happening today at the close? My broker said it’s 1: 80 - so we are losing tons of shares. My break even was 3.00 - Now it will be 244.00. (Divide your number of shares by 80) I’m going from 2200 shares to 27. Isn’t this a joke???

User Image Nyxy Posted - 1 week ago

$PIRS so stick split is confirmed?

User Image ibioRz Posted - 1 week ago

$PIRS move

User Image Mattw0502 Posted - 1 week ago

$PIRS

User Image Acolyte Posted - 1 week ago

$PIRS any news?

User Image RollingDollar Posted - 1 week ago

$PIRS

User Image RollingDollar Posted - 1 week ago

$PIRS .

User Image Jdubs48 Posted - 1 week ago

$CCTG I am ready! $AREC $CCTG $GNS $MSAI $PIRS

User Image Stocksrockman Posted - 1 week ago

$CCTG the fun starts back up at 4 AM. Be ready. The work ethic from bulls here is quite amazing. Everyone is slapping and holding. $GNS looks ready again $AREC is reversing $MSAI a beast. I mentioned at $2 in discord $PIRS could bounce off support here

User Image JohnS13 Posted - 1 week ago

$PIRS so Steve turns down a deal seeking a better one…they still could be at the table…he must feel confident about our place in the market…the BIGS must be okay with the initial rejection

User Image dhovekamp42 Posted - 2 weeks ago

@Rabinovich @JamesAnthonyR @KonaSpartan simply read the new $PIRS 10k risks section and you know what we are up to 4 now with www.pieris.com https://content.equisolve.net/sec/0001437749-24-010123/pirs20231231_10k.htm

User Image JamesAnthonyR Posted - 2 weeks ago

$PIRS why can’t everyone just let this ship sink in peace. Right now the stock is trading like a 2 or 3 year call option. If no news comes out, each quarter that goes by this will sink in proportion to cash burnt. Simple enough, anyone that is holding is hoping for a miracle that something else happens in the meantime. If you are already down big, might as well hold from here. Otherwise I would not be buying more. It would not take much for this to gain exponentially from here, but you also have to take into account that Yoder has failed us more times than not. Just my take on it

User Image Rabinovich Posted - 2 weeks ago

$PIRS What I find totally hilarious is how pumpers believe (better said: hope) that PIRS "partners" will chose to save PIRS by progressing the studies into phase 2 and paying millstones, instead of simply waiting PIRS to perish in 1-2 years and progress afterwards without any potential financial obligation. None of the BP "partners" depend on the prompt progress of these studies, which cannot be said of PIRS. Thanks Yoda for putting the company, in this dead-end position. No regrets!

User Image joe77w Posted - 2 weeks ago

$PIRS $20M royalties May Be monetized well before clinical trials timelines; reverse merger and Pirs 343 sale or partnership still possible; cash dividends likely. I am in.

User Image greenype Posted - 2 weeks ago

$PIRS when will the aggregated $20m milestone be paid (if paid)? We don't have to guess, let's take a look at the available data. These are the estimated phase 1 completion dates for every compound: - SGN-BB228. Primary completion: 2025-10-31 https://clinicaltrials.gov/study/NCT05571839 - S095012/PRS-344. Primary completion: 2027-10-31 https://clinicaltrials.gov/study/NCT05159388 - BOR-342. Time of last data collection: 2026-10-31 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385633 Conclusion: the milestone will be paid between 2026 and 2028. Again, if paid. I ask the same question to longs: is this failed stock really the best investment for your hard-earned money? there are MUCH better opportunities out there, just look.

User Image ibioRz Posted - 2 weeks ago

$PIRS Holding tight!!!

User Image ibioRz Posted - 03/31/24

$PIRS what be your life tomorrow?

User Image GermanJay Posted - 03/30/24

@ATMOIL who Cares about institutions? Ive seen plenty of stocks that failed even with high institutional ownership and also Partnerships (see $PIRS)

User Image greenype Posted - 03/30/24

$PIRS the only "good" news of the 10-K is that shares outstanding somehow stay the same. Other than that everything is worse: Less cash, less drugs and highest delisting risk than ever before. Following the winding down of the company, Nasdaq may consider it a "shell" and delist it (read that part). Also the company still not in compliance with the $1 rule after 2 extensions

User Image greenype Posted - 03/30/24

$PIRS PRS-220 discontinued, as per the 10-K. PRS-400 nowhere to be found. Remember they were supposed to release phase 1 data at some point? now we know why they didn't, the programs are dead

User Image joe77w Posted - 03/30/24

$PIRS catalysts are (to receive cash dividends) : 1) CINREBAFUSP (PIRS343) outright sale, outlicense agmt; 2) ROYALTIES MONETIZATION AGMT : value depends on clinical trials results and phase level; 3) 2 preclinical compounds exercise by Pfizer may generate immediate milestone payments and potential royalties; 4) 3 PH1 clinical trials results and ph2 start May bring upto 20 mln USD (medium term); 5) 3 pivotal trials starts may bring upto 55 mln USD (long term); a pH 2 May Be pivotal, not only a ph3. 6) IP Is very strong, ANTICALIN library has potential to be sold or outlicensed; 7) Company may still seek strategic corporate deals.

Analyst Ratings
Baird Outperform Mar 13, 20
Baird Neutral Jul 30, 19
Baird Outperform May 14, 19
Cowen & Co. Outperform May 4, 18
Evercore ISI Group Outperform Mar 19, 18
Jefferies Buy Mar 19, 18
William Blair Outperform Jan 17, 18
Rodman & Renshaw Buy May 30, 17
JMP Securities Market Outperform Mar 9, 16
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KIRITSY CHRISTOPHER P Director Director May 25 Buy 0.85 10,000 8,500 20,000 05/30/23
Demuth Tim Chief Medical Office.. Chief Medical Officer May 13 Buy 1.71 6,000 10,260 6,000 05/16/22